期刊文献+

2011年中国CHINET克雷伯菌属细菌耐药性监测 被引量:25

CHINET 2011 surveillance of antibiotic resistance in Klebsiellaspp.in China
暂未订购
导出
摘要 目的了解2011年中国CHINET所属15所医院临床分离的克雷伯菌属细菌的耐药情况。方法采用纸片扩散法(K-B法)和自动化仪器对临床分离株作药敏试验,并按CLSI 2011年版标准判断药敏试验结果。结果共收集中国CHINET细菌耐药性监测网15所医院分离的肺炎克雷伯菌6 390株、产酸克雷伯菌547株、肺炎克雷伯菌臭鼻亚种42株和其他克雷伯菌属细菌2株,其中儿童及青少年(0~17岁)来源的克雷伯菌属细菌占19.3%(1 346/6 981)。56.3%分离株来源于呼吸道标本。药敏试验结果显示,克雷伯菌属细菌对亚胺培南、美罗培南和厄他培南3种碳青霉烯类抗生素的耐药率分别为9.3%、9.4%和11.3%,对头孢哌酮-舒巴坦和哌拉西林-他唑巴坦的耐药率分别为15.8%和15.9%。15所医院均分离出对碳青霉烯类抗生素(亚胺培南或美罗培南)耐药菌株,其中肺炎克雷伯菌642株,产酸克雷伯菌33株。结论克雷伯菌属细菌对碳青霉烯类抗生素、头孢哌酮-舒巴坦和哌拉西林-他唑巴坦仍保持高度敏感性,按CLSI 2011年版新标准,对碳青霉烯类抗生素耐药菌株的分离率已近10.0%,且耐药株仍主要集中于华东地区,加强医院感染控制至关重要。 Objective To investigate the antimicrobial resist- ance in the clinical Klebsiella strains isolated from the 15 hospitals participating in China CHINET in 2011. Methods Disc diffusion technique (Kirby-Bauer method) and automat- ic microbiology analysis system were employed to determine the antimicrobial resistance. WHONET 5 . 6 software was used for analysis according to Clinical and Laboratory Stand- ards Institute (CLSI) 2011 breakpoints. Results A total of 6 98l clinical isolates of Klebsiella spp. were analyzed in 2011, including K. pneumoniae (6 390), K. oxytoca (547), Kleb siella pneumoniae subsp. Ozaenae (42) and other Klebsiella species (2). About 19.3% (1 346/6 981) of the Klebsiella strains were isolated from children or adolescence (0 18 years of age). According to the antimicrobial susceptibility test, all the isolates showed the lowest resistance rate to imipenem (9.3%), meropenem (9.4%) and ertapenem (11.3%), followed by cefopera zone-sulbactam (15.8%) and piperacillin-tazobaetam (15.9%). A total of 642 K. pneumoniae strains and 33 K. oxytoca strains were identified as resitant to either imipenem or meropenem among all the isolates from 15 hospitals. Conclusions Clinical Kleb- siella spp. isolates demonstrate lower resistance to carbapenems, cefoperazone-sulbactam and piperacillin tazobactam. The preva lence of earbapenem-resistant Klebsiella strains is still increasing in China, nearly 10.0% in 2011, especially in Eastern China. It is critical to make every effort to control hospital infections.
出处 《中国感染与化疗杂志》 CAS 北大核心 2013年第5期331-336,共6页 Chinese Journal of Infection and Chemotherapy
关键词 克雷伯菌属 耐药性监测 药敏试验 Klebsiella spp. resistance surveillance susceptibility testing
  • 相关文献

参考文献9

  • 1Clinical and Laboratory Standads Institute. Performance Standards for Antimicrobial Susceptibiliity Testing[S] . Sixteenth Infor- mational Supplement , 2010 , M100- S20.
  • 2European Committee on Antimicrobial Susceptibility Testing (EUCAST). 2012. Breakpoint tables for interpretation of MICs and zone diametersES~. Version 2.0, valid from 2012 01-01. http://www, eucast, org/elinical_breakpoints/.
  • 3郑港森,宋秀宇,黄朝阳,吴维生.对肺炎克雷伯菌产β-内酰胺酶的检测及耐药性分析[J].检验医学与临床,2008,5(3):142-144. 被引量:12
  • 4Cai JC, Zhou HW, Zhang R,et al. Emergence of Serratia marcescens , Klebsiella pneumoniae , and Escherichia coli iso- lates possessing the plasmid-mediated carbapenem-hydroly-zing beta-lactamase KPC-2 in intensive care units of a Chinese hospital[J].Antimicrob Agents Chemother, 2008,52 (6) 2014-2018.
  • 5卓超,苏丹虹,倪语星,孙景勇,俞云松,杨青,孙自镛,简翠,汪复,朱德妹,胡付品,蒋晓飞,王传清,王爱敏,徐元宏,沈继录,徐英春,孙宏莉,张泓,李万华,单斌,杜艳,张朝霞,季萍,贾蓓,黄文祥,魏莲花,吴玲,胡云建,艾效曼.2009年中国CHINET大肠埃希菌和克雷伯菌属细菌耐药性监测[J].中国感染与化疗杂志,2010,10(6):430-435. 被引量:81
  • 6卓超,苏丹虹,倪语星,孙景勇,汪复,朱德妹,胡付品,徐英春,张小江,俞云松,杨青,陈中举,孙自镛,张朝霞,季萍,单斌,杜艳,张泓,孔菁,徐元宏,沈继录,王传清,王爱敏,贾蓓,黄文祥,魏莲花,吴玲,胡云建,艾效曼.2010年CHINET克雷伯菌属细菌耐药性监测[J].中国感染与化疗杂志,2012,12(3):174-179. 被引量:34
  • 7Lee CM, Liao CH, Lee WS, et al. Outbreak of Klebsiella pneumoniae carbapenemase-2-producing K. pneumoniae se quenee type J1 in Taiwan in 2011 [J]. Antimicrob Agents Chemother, 2012, 56(10) :5016 -5022.
  • 8Castanheira M, Sader HS, Deshpande LM, et al. Antimicrobial activities of tigecycline and other broad-spectrum antimicrobi als tested against serine carbapenemase and metallo beta lac tamase-produeing Enterobacteriaceae: Report from the SEN TRY Antimicrobial Surveillance Program[J]. Antimicrob A gents Chemother,2008,52(2) : 570 573.
  • 9王辉,倪语星,陈民钧,胡必杰,王明贵,陈佰义,胡继红,胡云建.新型甘氨酰环素类抗菌药物替加环素的体外药敏试验操作规程[J].中华检验医学杂志,2009,32(11):1208-1213. 被引量:65

二级参考文献41

  • 1卓超,苏丹虹,倪语星,孙景勇,俞云松,杨青,孙自镛,简翠,汪复,朱德妹,胡付品,蒋晓飞,王传清,王爱敏,徐元宏,沈继录,徐英春,孙宏莉,张泓,李万华,单斌,杜艳,张朝霞,季萍,贾蓓,黄文祥,魏莲花,吴玲,胡云建,艾效曼.2009年中国CHINET大肠埃希菌和克雷伯菌属细菌耐药性监测[J].中国感染与化疗杂志,2010,10(6):430-435. 被引量:81
  • 2冯福英,兰小鹏,杨湘越,张亚彬,胡辛兰,郭容英.大肠埃希菌和肺炎克雷伯菌质粒AmpC酶基因型及流行病学分析[J].中华检验医学杂志,2007,30(3):314-318. 被引量:15
  • 3王冬国,周铁丽.质粒介导产AmpC酶大肠埃希菌、肺炎克雷伯菌AmpC基因型检测与分析[J].中华医院感染学杂志,2007,17(7):782-785. 被引量:14
  • 4Petersen PJ, Jacobus NV, Weiss WJ, et al. In vitro and in vivo antibacterial activities of a novel glycylcycline, the 9-t-butylglycylamido derivative of minocycline (GAR-936). Antimicrob Agents Chemother, 1999, 43:738-744.
  • 5Bradford P. Tigecycline: a first in class glycylcycline. Clin Micro Newsl, 2004,26:163-168.
  • 6Felmingham D. Tigecycline-the first glycylcycline to undergo clinical development: an overview of in vitro activity compared to tetracycline. J Chemother, 2005,17 Suppl 1:5-11.
  • 7Chopra I, Hawkey PM, Hinton M. Tetracyclines, molecular and clinical aspects. J Antimicrob Chemother,1992 ,29 :245-277.
  • 8Schnappinger D, Hillen W. Tetraeyclines: antibiotic action, uptake, and resistance mechanisms. Arch Mierobiol, 1996, 165:359-369.
  • 9Bauer G, Berens C, Projan SJ, et al. Comparison of tetracycline and tigecycline binding to ribosomes mapped by dimethylsulphate and drugdirected Fe^2 + cleavage of 16S rRNA. J Antimicrob Chemother, 2004, 53:592-599.
  • 10Olson MW, Ruzin A, Feyfant E, et al. Functional, biophysical, and structural bases for antibacterial activity of tigecycline. Antimicrob Agents Chemother, 2006,50 : 2156 -2166.

共引文献188

同被引文献193

引证文献25

二级引证文献244

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部